PASI
The PASI is the gold-standard clinician-administered measure of psoriasis severity and extent. Developed by Fredriksson and Pettersson in 1978, it evaluates four cardinal clinical signs (erythema, induration, desquamation) across four body regions, each weighted by anatomical importance. PASI is the most widely used endpoint in psoriasis clinical trials and is endorsed by regulatory agencies (FDA, EMA) and international dermatology societies.
Source record
Citations copied verbatim from the method’s source record. No claim-level verification is inferred from them.
- Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244. · DOI 10.1159/000250839
- Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii65-ii68. · DOI 10.1136/ard.2004.031237
Curated claims
Claims persisted in the evidence ledger, each with its own assessment.
This view does not invent a claim assessment when the ledger has none.
Related methods
Generated from the method graph and shown as machine-suggested relations — no evidence claim is inferred.